BUYRAK ARTERIAYALARI ATEROSKLEROZIDA ANGIOTENSINOGEN (AGT) GENINING RO‘LI
Kalit so'zlar
https://doi.org/10.47390/Med-pro/v3i6y2025/N03Kalit so'zlar
surunkali buyrak kasalligi, buyrak arteriyalarining aterosklerozi, APOE, gen, polimorfizmAnnotasiya
Yurak-qon tomir kasalliklari butun dunyo bo‘ylab kasallanish va o‘limning yetakchi sabablaridan biri bo‘lib qolmoqda, bunda ateroskleroz asosiy patologiya hisoblanadi. Aterosklerozning turli ko‘rinishlari orasida buyrak arteriyalarining aterosklerotik zararlanishi (BAAZ) alohida klinik ahamiyatga ega, chunki u renovaskulyar gipertenziya, surunkali buyrak kasalligi (SBK) va yurak-qon tomir asoratlari xavfining ortishi bilan bog‘liq. Diagnostika va davolash usullarining rivojlanishiga qaramay, BAAZ ko‘pincha hech qanday belgisiz kechadi va ko‘pincha kech bosqichlarda aniqlanadi, bu esa xavf omillarini erta aniqlashni juda muhim qiladi
Manbalar
1. Sezer S, Tutal E, Arat Z, et al. Arterial atherosclerosis in patients with chronic kidney disease and its relationship with serum and tissue endothelin‑1. *J Ren Nutr.* (corrected). PMID: 19841523. ([PubMed][5])
2. Dhaun N, Webb DJ, Kluth DC. Endothelin‑1 and the kidney – beyond BP. *Br J Pharmacol.* 2012;167(4):720–731. ([NCBI][4])
3. Cho ME, Brunt VE, Shiu YT, et al. Endothelial dysfunction in chronic kidney disease: a clinical perspective. *Am J Physiol Heart Circ Physiol.* (PMC). ([PMC][2])
4. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. *PubMed.* PMID: 23243212. ([PubMed][7])
5. Namuun G, Kadota A, Hisamatsu T, et al. Relationship between Kidney Function and Subclinical Atherosclerosis Progression Evaluated by Coronary Artery Calcification. *J Atheroscler Thromb.* 2021;29(9):1359–1371. ([PMC][8])
6. Назарова, Н. О., & Жаббаров, О. О. (2025). РИСК АТЕРОСКЛЕРОЗА У ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК.
7. Khaydarov, R., Umarova, Z. F., & Nazarova, N. O. (2025). RENAL HEMODYNAMIC CHANGES IN LUPUS NEPHRITIS. Медицинский журнал молодых ученых, (13 (03)), 216-220.
8. Nazarova, N. O., & Jabbarov, O. O. (2025). APOL1 NEPHROPATHY RISK VARIANTS AND INCIDENT CARDIOVASCULAR DISEASE EVENTS. Медицинский журнал молодых ученых, (13 (03)), 60-63.
9. Salimov, J. K., Umarova, Z. F., & Nazarova, N. O. (2025). THE USE OF ENOXAPARIN AND RIVAROXABAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Инновационные исследования в современном мире: теория и практика, 4(3), 105-106
